Fasting serum concentration of apolipoprotein B48 represents residual risks in patients with new-onset and chronic coronary artery disease.

Abstract

BACKGROUND:

To identify new therapeutic targets for coronary artery disease (CAD), we investigated whether fasting serum concentration of apolipoprotein (apo) B48 could be a marker for CAD.

METHODS:

Patients with CAD were divided into those with new-onset CAD [i.e., those receiving percutaneous coronary intervention (PCI) for the first time] and those with chronic CAD (i.e., those receiving follow-up coronary angiography). Fasting serum biochemical analyses were performed on admission and 6 months after the PCI.

RESULTS:

On admission, serum LDL-C concentrations in patients with chronic CAD (n=138), presumably receiving statin treatment, were lower than in patients with new-onset CAD (n=50, p<0.02) or without CAD (n=71, p<0.001). Nevertheless, apoB48 was higher in CAD patients than in those without CAD (p<0.001). After adjusting for classic cardiovascular risk factors, multivariate logistic regression analyses showed apoB48 to be an independent predictor of coronary risk in new-onset or chronic CAD, irrespective of the LDL-C levels. Moreover, apoB48 was markedly increased during the follow-up period in CAD patients having new lesion progression after the prior PCI.

CONCLUSION:

Fasting serum apoB48 concentration could be a marker of new onset as well as chronic CAD, and predict new lesion progression in secondary prevention.

• Authors: Kenta Mori, Tatsuro Ishida, Tomoyuki Yasuda, Tomoko Monguchi, Maki Sasaki, Kensuke Kondo, Minoru Hasokawa, Hideto Nakajima, Yoko Haraguchi, Li Sun, Masakazu Shinohara, Ryuji Toh, Kunihiro Nishimura, Ken-ichi Hirata
• Journal: Clinica chimica acta; international journal of clinical chemistry (Clin Chim Acta) Vol. 421 Pg. 51-6 (Jun 05 2013) ISSN: 1873-3492 [Electronic] Netherlands
• PMID: 23428589 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2013 Elsevier B.V. All rights reserved.

Chemical References

• Apolipoprotein B-48
• Biomarkers
• Hydroxymethylglutaryl-CoA Reductase Inhibitors

Topics

• Aged
• Apolipoprotein B-48 (blood)
• Biomarkers (blood)
• Chronic Disease
• Coronary Angiography
• Coronary Artery Disease (blood, diagnosis, diagnostic imaging, drug therapy)
• Fasting
• Female
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
• Logistic Models
• Male
• Middle Aged
• Percutaneous Coronary Intervention
• Risk Factors